Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 26

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Breast cancer metastatic

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Drug Combination for Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Endometrial cancer+12

Recruiting

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:AstraZeneca AB

Hormone-refractory prostate cancer+2

Recruiting

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Karolinska Institutet

Ovarian cancer

Recruiting

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Infertility

Recruiting

Study Comparing Corifollitropin Alfa and Modified Natural Cycles for Women with Subfertility and Low Ovarian Response

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Corifollitropin Alfa
  • Sponsor:Universitair Ziekenhuis Gent

Breast cancer

Recruiting

Study on 18F-FES PET/MRI for Patients with Luminal A and Lobular Breast Cancer to Improve Treatment Decisions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Universita' Vita-salute S. Raffaele

Breast cancer

Recruiting

Study on Edotreotide for Detecting Somatostatin Receptors in Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Edotreotide
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Hormone-refractory prostate cancer

Recruiting

Study on the Safety and Effects of Lutetium (177Lu) rhPSMA-10.1 Injection in Men with Advanced Prostate Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:177Lu-Rhpsma-10.1
  • Sponsor:Blue Earth Therapeutics Limited

Infertility female

Recruiting

Study on Exercise, Mediterranean Diet, and Aspirin for Women with Infertility Undergoing In Vitro Fertilization

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Behcet's syndrome

Recruiting

Study on Apremilast for Treating Oral Ulcers in Children with Behçet's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Prostate cancer

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan for Patients with High-Risk Prostate Cancer After Radiation and Hormone Therapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Prostate cancer

Recruiting

Study on High-Risk Prostate Cancer Treatment Using Darolutamide, Relugolix, and Drug Combination for Eligible Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Ziekenhuis Aan De Stroom

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.